TWO · 7729.TWO
Steminent Biotherapeutics Inc.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
Loading market information…
TWO · 4168.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
GlycoNex Incorporation’s forward annual dividend is NT$0.01 per share, paid annual. The forward yield is 0.06% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow GlycoNex Incorporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$155.00NT$0.00 (0.0%)
Hcmed’s quoted price sits in the upper half of its reported 52-week range, 11.43% below the high.
NT$26.95+NT$0.55 (+2.08%)
Intech Biopharm Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.56% below the high.
NT$26.40-NT$0.40 (-1.49%)
Taiwan Bio Therapeutics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
NT$29.45NT$0.00 (0.0%)
Genomics BioSci & Tech. Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.08% below the high.
NT$43.30-NT$0.30 (-0.69%)
HeXun Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.53% below the high.
NT$20.80-NT$0.30 (-1.42%)
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
NT$9.42-NT$0.25 (-2.59%)
Sunny Pharmtech Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.54% below the high.
